Sangamo Therapeutics’ (SGMO) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright restated their buy rating on shares of Sangamo Therapeutics (NASDAQ:SGMO) in a report released on Thursday morning,Benzinga reports. The firm currently has a $10.00 price objective on the biopharmaceutical company’s stock. HC Wainwright also issued estimates for Sangamo Therapeutics’ FY2028 earnings at $0.64 EPS.

SGMO has been the subject of several other reports. StockNews.com assumed coverage on Sangamo Therapeutics in a report on Sunday, July 28th. They issued a “sell” rating for the company. Barclays raised their target price on Sangamo Therapeutics from $3.00 to $9.00 and gave the company an “overweight” rating in a report on Thursday.

Sangamo Therapeutics Trading Down 4.7 %

SGMO stock opened at $2.05 on Thursday. The company has a market cap of $427.73 million, a PE ratio of -2.73 and a beta of 1.10. The stock has a 50-day moving average price of $1.33 and a two-hundred day moving average price of $0.87. Sangamo Therapeutics has a 12-month low of $0.30 and a 12-month high of $3.18.

Sangamo Therapeutics (NASDAQ:SGMO) last posted its quarterly earnings results on Tuesday, November 12th. The biopharmaceutical company reported $0.04 EPS for the quarter, beating the consensus estimate of ($0.03) by $0.07. Sangamo Therapeutics had a negative net margin of 257.87% and a negative return on equity of 264.16%. The firm had revenue of $49.41 million for the quarter, compared to analyst estimates of $26.55 million. During the same quarter last year, the firm posted ($0.34) earnings per share. Equities analysts forecast that Sangamo Therapeutics will post -0.5 EPS for the current fiscal year.

Hedge Funds Weigh In On Sangamo Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. State Board of Administration of Florida Retirement System lifted its stake in shares of Sangamo Therapeutics by 61.1% in the first quarter. State Board of Administration of Florida Retirement System now owns 62,345 shares of the biopharmaceutical company’s stock worth $42,000 after acquiring an additional 23,650 shares in the last quarter. Meritage Portfolio Management raised its position in shares of Sangamo Therapeutics by 8.6% in the 3rd quarter. Meritage Portfolio Management now owns 85,000 shares of the biopharmaceutical company’s stock valued at $74,000 after purchasing an additional 6,740 shares in the last quarter. XTX Topco Ltd boosted its stake in shares of Sangamo Therapeutics by 167.8% during the 3rd quarter. XTX Topco Ltd now owns 103,716 shares of the biopharmaceutical company’s stock valued at $90,000 after buying an additional 64,981 shares during the last quarter. Wealth Enhancement Advisory Services LLC grew its position in shares of Sangamo Therapeutics by 55.4% during the third quarter. Wealth Enhancement Advisory Services LLC now owns 108,945 shares of the biopharmaceutical company’s stock worth $94,000 after buying an additional 38,850 shares in the last quarter. Finally, Cubist Systematic Strategies LLC bought a new stake in shares of Sangamo Therapeutics in the second quarter worth $67,000. 56.93% of the stock is owned by hedge funds and other institutional investors.

Sangamo Therapeutics Company Profile

Sangamo Therapeutics, Inc, a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease.